About ABBV-744 as a potential therapeutic option for aggressive cancers
These side effects had been notably milder when compared with an inhibitor of each bromodomains. A detailed molecular Investigation also discovered that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylor- "Our study revealed the vital position on the KLF16/MYC regulatory axis in modulatin